Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression
- 30 September 2006
- journal article
- research article
- Published by Elsevier BV in Neuropharmacology
- Vol. 51 (3), 578-586
- https://doi.org/10.1016/j.neuropharm.2006.04.017
Abstract
The aim of the present study was to examine the effect of the selective 5-HT7 receptor antagonist SB 269970 (0.25–20 mg/kg) in the behavioral tests commonly used for predicting anxiolytic- and antidepressant-like activity. Diazepam and imipramine were used as standard drugs. SB 269970 (in one medium dose of 0.5 or 1 mg/kg) exerted a specific antianxiety-like effect in the Vogel drinking test in rats, in the elevated plus-maze test in rats and in the four-plate test in mice. Moreover, SB 269970 (in one medium dose of 5 or 10 mg/kg) showed antidepressant-like activity in the forced swimming and the tail suspension tests in mice. At the same time, the tested compound at doses of 1–20 mg/kg did not change the spontaneous locomotor activity of mice. The potential anxiolytic and antidepressant effects produced by SB 269970 were weaker than those of the reference drugs employed. It is noteworthy that the active doses of SB 269970 were devoid of any visible motor side-effects. In conclusion, the results of our studies indicate that 5-HT7 receptor antagonists may play a role in the therapy of both anxiety and depression.Keywords
This publication has 45 references indexed in Scilit:
- The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in miceNeuroscience & Biobehavioral Reviews, 2005
- Functional, molecular and pharmacological advances in 5-HT7 receptor researchTrends in Pharmacological Sciences, 2004
- Mice lacking 5‐HT7 receptors show specific impairments in contextual learningEuropean Journal of Neuroscience, 2004
- The effect of SB‐269970, a 5‐HT7 receptor antagonist, on 5‐HT release from serotonergic terminals and cell bodiesBritish Journal of Pharmacology, 2001
- A Novel, Potent, and Selective 5-HT7Antagonist: (R)-3-(2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970)Journal of Medicinal Chemistry, 2000
- Role of the Serotonergic System in the Pathogenesis of Major Depression and Suicidal BehaviorNeuropsychopharmacology, 1999
- Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive–Compulsive and Panic DisordersNeuropsychopharmacology, 1999
- Pindolol‐insensitive [3H]‐5‐hydroxytryptamine binding in the rat hypothalamus; identity with 5‐hydroxytryptamine7 receptorsBritish Journal of Pharmacology, 1999
- Animal models of ??anxiety??: where next?Behavioural Pharmacology, 1997
- Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the ratPharmacology Biochemistry and Behavior, 1986